Pyxis Oncology Stock Fundamentals
| PYXS Stock | USD 1.89 0.01 0.53% |
Pyxis Oncology fundamentals help investors to digest information that contributes to Pyxis Oncology's financial success or failures. It also enables traders to predict the movement of Pyxis Stock. The fundamental analysis module provides a way to measure Pyxis Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pyxis Oncology stock.
At this time, Pyxis Oncology's Net Interest Income is comparatively stable compared to the past year. Interest Income is likely to gain to about 7.3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 20.7 M in 2024. Pyxis | Select Account or Indicator |
Pyxis Oncology Company Return On Equity Analysis
Pyxis Oncology's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Pyxis Oncology Return On Equity | -0.39 |
Most of Pyxis Oncology's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pyxis Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Pyxis Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Pyxis Oncology has a Return On Equity of -0.3934. This is 98.36% lower than that of the Biotechnology sector and 98.92% lower than that of the Health Care industry. The return on equity for all United States stocks is 26.9% higher than that of the company.
Pyxis Oncology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pyxis Oncology's current stock value. Our valuation model uses many indicators to compare Pyxis Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pyxis Oncology competition to find correlations between indicators driving Pyxis Oncology's intrinsic value. More Info.Pyxis Oncology is regarded fourth in return on equity category among its peers. It is regarded third in return on asset category among its peers . At this time, Pyxis Oncology's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Pyxis Oncology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Pyxis Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pyxis Oncology's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pyxis Oncology could also be used in its relative valuation, which is a method of valuing Pyxis Oncology by comparing valuation metrics of similar companies.Pyxis Oncology is currently under evaluation in return on equity category among its peers.
Pyxis Fundamentals
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (3.99) % | ||||
| Current Valuation | (11.29 M) | ||||
| Shares Outstanding | 59.47 M | ||||
| Shares Owned By Insiders | 24.54 % | ||||
| Shares Owned By Institutions | 54.50 % | ||||
| Number Of Shares Shorted | 5.86 M | ||||
| Price To Book | 0.74 X | ||||
| Price To Sales | 7.00 X | ||||
| EBITDA | (78.49 M) | ||||
| Net Income | (73.79 M) | ||||
| Cash And Equivalents | 223.36 M | ||||
| Cash Per Share | 7.48 X | ||||
| Total Debt | 21.33 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 15.19 X | ||||
| Book Value Per Share | 2.58 X | ||||
| Cash Flow From Operations | (70.71 M) | ||||
| Short Ratio | 10.78 X | ||||
| Earnings Per Share | (1.06) X | ||||
| Price To Earnings To Growth | 0.01 X | ||||
| Target Price | 10.67 | ||||
| Number Of Employees | 54 | ||||
| Beta | 1.28 | ||||
| Market Capitalization | 112.98 M | ||||
| Total Asset | 173.73 M | ||||
| Retained Earnings | (286.23 M) | ||||
| Working Capital | 98.84 M | ||||
| Net Asset | 173.73 M |
About Pyxis Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pyxis Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pyxis Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pyxis Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 8.8 M | 4.4 M | |
| Cost Of Revenue | 2 M | 1.5 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.